QURE News

uniQure N.V. Securities Fraud Class Action Result of FDA Approval Delay and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC

Pomerantz LLP Issues Alert Regarding Shareholder Class Action Involving uniQure N.V. – QURE

Class Action Filed Against uniQure N.V. (QURE) Seeking Recovery for Investors – Contact Levi & Korsinsky

QURE INVESTOR ALERT: uniQure Faces Securities Class Action Over AMT-130 Clinical Trial Design - Hagens Berman

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages uniQure N.V. Investors to Secure Counsel Before Important Deadline in Securities Class Action - QURE

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman LLC Urges uniQure N.V. Investors to Act: Class Action Filed Alleging Investor Harm

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

QURE Investors Have Opportunity to Lead uniQure N.V. Securities Fraud Lawsuit with the Schall Law Firm

Portnoy Law Firm Announces Class Action on Behalf of uniQure N.V. Investors